Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
We are passionate about enriching patients health, and our team is here to help you feel your best
4 FDA Compounding Policy: Category 1 peptide reclassification, February 2026
Additionally, research published in Drug Testing and Analysis characterizing AOD9604 metabolism and confirming its C-terminal HGH fragment structure, supporting its classification as a non-IGF-1-stimulating lipolytic agent has been used by clinicians evaluating the compound for metabolic applications
Published clinical research has reported dose dependent body weight reductions with once weekly cagrilintide in participants with overweight or obesity, and combination trials with semaglutide have reported greater weight loss than either component alone
Always consult a licensed physician or qualified healthcare provider before considering any peptide-based intervention
